Sharon M Moe1, Ravi Thadhani. 1. aIndiana University School of Medicine and Roudebush Veterans Administration Medical Center, Indianapolis, Indiana bMassachusettes General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The treatment of chronic kidney disease-mineral bone disorder (CKD-MBD) has traditionally focused on improvement in biochemical parameters of the disease. However, studies evaluating hard clinical end points or surrogate end points are limited. RECENT FINDINGS: Two randomized controlled trials have recently been published. In the EVOLVE study (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events), cinacalcet was compared with placebo in 3883 haemodialysis patients with secondary hyperparathyroidism. The primary end point (death, myocardial infarction, unstable angina, heart failure or peripheral vascular disease) in an unadjusted intention-to-treat analysis was not significant [hazard ratio 0.93; 95% confidence interval (CI) 0.85-1.02, P=0.11]. However, the pre-specified secondary end points of an adjusted intention-to-treat analysis (hazard ratio 0.88; 95% CI 0.79-0.97, P=0.008) were significant. In the PRIMO (Paricalcitol Capsule Benefits in Renal Failure Induced Cardiac Morbidity) trial, 227 patients with CKD stage 3-4 and left ventricular hypertrophy by echocardiography were randomized to paricalcitol or placebo. The primary end point of change in left ventricular mass index by MRI after 12 months was not different between the two groups, but the prespecified end point of cardiovascular-related hospitalizations was reduced in the paricalcitol-treated group (P=0.04). SUMMARY: The results of these two randomized controlled trials have negative primary end points but significant secondary end points and thus require physicians to individualize therapies for the treatment of secondary hyperparathyroidism.
RCT Entities:
PURPOSE OF REVIEW: The treatment of chronic kidney disease-mineral bone disorder (CKD-MBD) has traditionally focused on improvement in biochemical parameters of the disease. However, studies evaluating hard clinical end points or surrogate end points are limited. RECENT FINDINGS: Two randomized controlled trials have recently been published. In the EVOLVE study (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events), cinacalcet was compared with placebo in 3883 haemodialysis patients with secondary hyperparathyroidism. The primary end point (death, myocardial infarction, unstable angina, heart failure or peripheral vascular disease) in an unadjusted intention-to-treat analysis was not significant [hazard ratio 0.93; 95% confidence interval (CI) 0.85-1.02, P=0.11]. However, the pre-specified secondary end points of an adjusted intention-to-treat analysis (hazard ratio 0.88; 95% CI 0.79-0.97, P=0.008) were significant. In the PRIMO (Paricalcitol Capsule Benefits in Renal Failure Induced Cardiac Morbidity) trial, 227 patients with CKD stage 3-4 and left ventricular hypertrophy by echocardiography were randomized to paricalcitol or placebo. The primary end point of change in left ventricular mass index by MRI after 12 months was not different between the two groups, but the prespecified end point of cardiovascular-related hospitalizations was reduced in the paricalcitol-treated group (P=0.04). SUMMARY: The results of these two randomized controlled trials have negative primary end points but significant secondary end points and thus require physicians to individualize therapies for the treatment of secondary hyperparathyroidism.
Authors: W N Suki; R Zabaneh; J L Cangiano; J Reed; D Fischer; L Garrett; B N Ling; S Chasan-Taber; M A Dillon; A T Blair; S K Burke Journal: Kidney Int Date: 2007-08-29 Impact factor: 10.612
Authors: S Moe; T Drüeke; J Cunningham; W Goodman; K Martin; K Olgaard; S Ott; S Sprague; N Lameire; G Eknoyan Journal: Kidney Int Date: 2006-06 Impact factor: 10.612
Authors: N Koh; T Fujimori; S Nishiguchi; A Tamori; S Shiomi; T Nakatani; K Sugimura; T Kishimoto; S Kinoshita; T Kuroki; Y Nabeshima Journal: Biochem Biophys Res Commun Date: 2001-02-02 Impact factor: 3.575
Authors: Olga I Kolek; Eric R Hines; Marci D Jones; Loren K LeSueur; Maciej A Lipko; Pawel R Kiela; James F Collins; Mark R Haussler; Fayez K Ghishan Journal: Am J Physiol Gastrointest Liver Physiol Date: 2005-07-14 Impact factor: 4.052
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2013-02-26 Impact factor: 4.310
Authors: Glenn M Chertow; Lara B Pupim; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drueke; Jürgen Floege; William G Goodman; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Moetaz Albizem; Kurt Olson; Preston Klassen; Patrick Parfrey Journal: Clin J Am Soc Nephrol Date: 2007-08-16 Impact factor: 8.237
Authors: Cláudia Ribeiro; Maria Goretti Moreira Guimarães Penido; Milena Maria Moreira Guimarães; Marcelo de Sousa Tavares; Bruno das Neves Souza; Anderson Ferreira Leite; Leonardo Martins Caldeira de Deus; Lucas José de Campos Machado Journal: World J Nephrol Date: 2016-09-06
Authors: Christopher L Newman; Nannan Tian; Max A Hammond; Joseph M Wallace; Drew M Brown; Neal X Chen; Sharon M Moe; Matthew R Allen Journal: Am J Nephrol Date: 2016-02-17 Impact factor: 3.754
Authors: Daniel W Coyne; Seth Goldberg; Mark Faber; Cybele Ghossein; Stuart M Sprague Journal: Clin J Am Soc Nephrol Date: 2014-06-26 Impact factor: 8.237
Authors: Antonio Bellasi; Mario Cozzolino; Fabio Malberti; Giovanni Cancarini; Ciro Esposito; Carlo Maria Guastoni; Patrizia Ondei; Giuseppe Pontoriero; Ugo Teatini; Giuseppe Vezzoli; Marzia Pasquali; Piergiorgio Messa; Francesco Locatelli Journal: J Nephrol Date: 2019-12-18 Impact factor: 3.902